A study published in PubMed highlights a case of metastatic urachal carcinoma showing a durable response to pembrolizumab despite low tumor mutational burden and microsatellite stability. This finding may inform future treatment strategies for similar cases.
metastatic urachal carcinoma with microsatellite stability and low tumor mutational burden achieving a durable response to pembrolizumab after platinum failure
Original title: “Metastatic Urachal Carcinoma With Microsatellite Stability and Low Tumor Mutational Burden Achieving a Durable Response to Pembrolizumab After Platinum Failure.”